INO-4700 + Placebo + INO-4700
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Conditions
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Trial Timeline
Jun 21, 2021 → Jan 19, 2023
NCT ID
NCT04588428About INO-4700 + Placebo + INO-4700
INO-4700 + Placebo + INO-4700 is a phase 2 stage product being developed by Inovio Pharmaceuticals for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The current trial status is completed. This product is registered under clinical trial identifier NCT04588428. Target conditions include Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04588428 | Phase 2 | Completed |
Competing Products
3 competing products in Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| recombinant human erythropoietin alfa + 0.9% NaCl | Johnson & Johnson | Phase 2/3 | 65 |
| Comparator: Placebo + Comparator: MK0724 | Merck | Phase 2 | 52 |
| Piracetam | UCB | Approved | 82 |